Evaluation of a new blood test for detecting multiple types of cancer early

The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom (UK). The study enrolled 13,035 men and women aged 50 to 77 years who did not have a cancer diagnosis at the time of enrollment. SUMMIT aims to further evaluate GRAIL’s blood test designed to detect a signal shared by multiple types of cancer, including lung cancer.

The participants are people at high risk of lung and other cancers due to a significant smoking history. Participants will be followed annually for three years and will then be followed for five years through national health registries as well as their medical records.

 
Determining feasibility of a lung screening program in the UK
Low dose computed tomography (LDCT) scan is an imaging method that can be used to help detect lung cancer in people at high risk for the disease. Currently, LDCT is not widely available in the UK. In addition to evaluating the ability of GRAIL’s blood test to detect a signal shared by multiple cancer types, SUMMIT aims to assess the feasibility of implementing a lung cancer screening program in the UK.

Thank you for your contribution
GRAIL and its collaborators would like to extend a big thank you to all the participants across the United Kingdom who contributed to the SUMMIT Study. Your participation in the SUMMIT Study helped GRAIL and its collaborators develop an important new multi-cancer early detection test.